

Medical Emergencies Related to Ethanol and Illicit Drugs at an Annual, Nocturnal, Indoor, Electronic Dance Music Event

Paul Calle, PhD;^{1,2} Nora Sundahl, MD;¹ Kristof Maudens, PhD;³ Sarah MR Wille, PhD;⁴ Diederik Van Sassenbroeck, PhD;² Koen De Graeve, MD;⁵ Stefan Gogaert, IR;⁶ Peter De Paepe, PhD;^{1,7} Dieter Devriese, MD;⁸ Geert Arno, RN;⁹ Peter Blanckaert, PhD¹⁰

1. Ghent University, Ghent, Belgium
2. Emergency Department, General Hospital Maria Middelaers, Ghent, Belgium
3. Toxicological Centre, University of Antwerp, Antwerp, Belgium
4. National Institute of Criminalistics and Criminology, Brussels, Belgium
5. Emergency Department, General Hospital Jan Palfijn, Ghent, Belgium
6. Belgian Red Cross, Mechelen, Belgium
7. Emergency Department, University Hospital, Ghent, Belgium
8. Emergency Department, General Hospital Saint Lucas, Ghent, Belgium
9. Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium
10. Belgian Early Warning System on Drugs, Scientific Institute of Public Health, Brussels, Belgium

Correspondence:

Paul Calle, PhD
General Hospital Maria Middelaers
Emergency Department
Ghent, Belgium
E-mail: paul.calle@ugent.be

Conflicts of interest: none

Keywords:

3,4-methylenedioxymethamphetamine (MDMA); ethanol; illicit drugs; mass gatherings; rave party

Abbreviations:

EDM: electronic dance music
GC-MS: gas chromatography-mass spectrometry
GHB: gamma-hydroxybutyric acid
HPLC: high-performance liquid chromatographic
ILT: I LOVE TECHNO
MDMA: 3,4-methylenedioxymethamphetamine
NPS: new psychoactive substances
THC: tetrahydrocannabinol

Abstract

Introduction: Medical problems are frequently encountered during electronic dance music (EDM) events.

Problem: There are uncertainties about the frequencies and severity of intoxications with different types of recreational drugs: ethanol, "classical" illicit party drugs, and new psychoactive substances (NPS).

Methods: Statistical data on the medical problems encountered during two editions of an indoor electronic dance event with around 30,000 attendants were retrieved from the Belgian Red Cross (Mechelen, Belgium) database. Data on drug use were prospectively collected from the patient (or a bystander), the clinical presentation, and/or toxicological screening.

Results: In the on-site medical station, 487 patients were treated (265 in 2013 and 222 in 2014). The most frequent reasons were trauma (n = 171), headache (n = 36), gastro-intestinal problems (n = 44), and intoxication (n = 160). Sixty-nine patients were transferred to a hospital, including 53 with severe drug-related symptoms. Analysis of blood samples from 106 intoxicated patients detected ethanol in 91.5%, 3,4-methylenedioxymethamphetamine (MDMA) in 34.0%, cannabis in 30.2%, cocaine in 7.5%, amphetamine in 2.8%, and gamma-hydroxybutyric acid (GHB) in 0.9% of patients (alone or in combination). In only six of the MDMA-positive cases, MDMA was the sole substance found. In 2014, the neuroleptic drug clozapine was found in three cases and ketamine in one. Additional analyses for NPS were performed in 20 cases. Only in one agitated patient, the psychedelic phenethylamines 25B-NBOMe and 25C-NBOMe were found.

Conclusions: At this particular event, recreational drug abuse necessitated on-site medical treatment in one out of 350 attendants and a hospital transfer in one out of 1,000. Ethanol remains the most frequently abused (legal) drug, yet classical illicit recreational drugs are also frequently (co-) ingested. The most worrying observation was high-risk poly-drug use, especially among MDMA users. Regarding NPS, the number of cases was low and the clinical presentations were rather mild. It should be stressed that these observations only apply to this particular event and cannot be generalized to other EDM events.

Calle P, Sundahl N, Maudens K, Wille SMR, Van Sassenbroeck D, De Graeve K, Gogaert S, De Paepe P, Devriese D, Arno G, Blanckaert P. Medical emergencies related to ethanol and illicit drugs at an annual, nocturnal, indoor, electronic dance music event. *Prehosp Disaster Med.* 2018;33(1):71-76.

Introduction

Many reports suggest that electronic dance music (EDM) events and illicit drug use are tightly connected, with a high prevalence of 3,4-methylenedioxymethamphetamine (MDMA), cocaine, amphetamine, cannabis, gamma-hydroxybutyric acid (GHB), and

Received: December 7, 2016

Revised: February 28, 2017

Accepted: May 12, 2017

Online publication: December 29, 2017

doi:10.1017/S1049023X17007099

ketamine ingestion.^{1–3} This phenomenon is worrisome as these substances, known as “party drugs,” “recreational drugs,” or “club drugs,” have been shown to cause serious health hazards and death.^{3–8}

The last few years, this important health care issue is further being complicated by a steadily increasing number of new psychoactive substances (NPS), also called “research chemicals” and “designer drugs.” Across the European Union, over 560 NPS are monitored, with 98 appearing for the first time in 2015.⁹ For most NPS, little knowledge regarding pharmacology and toxicology is available to users and caregivers, thereby contributing to major health problems, including fatalities.^{10–13} Additionally, ethanol consumption remains a huge problem in Europe. A 31.2% prevalence of heavy episodic ethanol drinking is found among youngsters (15–19 years of age), and the proportion of deaths attributable to ethanol is around 20.0% in the 15–19 years old age group and around 25.0% in the 20–29 years old age group.¹⁴

The main purpose of this prospective study was to describe the medical problems at the 2013 and 2014 editions of I LOVE TECHNO (ILT; Ghent, Belgium), one of Europe’s largest indoor EDM events. Focus was put on the impact of different types of recreational drugs: ethanol, “classical” illegal party drugs, and NPS. The results may assist medical caregivers and police forces in developing prevention strategies at large EDM events, and to optimize the on-site care.

Methods

Preventive Measures and On-Site Medical Support

The concept of the ILT event and the on-site medical care has been described previously.⁶ Briefly, first-aid Belgian Red Cross (Mechelen, Belgium) personnel, reinforced with five emergency physicians and six emergency nurses, treated less-serious illnesses and casualties in the medical station. If necessary, medical stabilization was started on-site, with subsequent transfer to one of the four nearby participating hospitals by one of the six stand-by ambulances.

Data Collection

As already described for the 2001 edition, all patients were registered by the Red Cross, and a standardized registration form with administrative and medical items was filled out by the caregivers.^{6,15} All apparently intoxicated patients judged by the attending physician to be in need of an intravenous line (for example, for the administration of benzodiazepines or fluids) were included in the toxicology study (irrespective of the patient’s age and the clinical presentation). For this sub-group, medical students prospectively recorded the clinical findings throughout the patient’s stay in the medical station. Information about the nature of the ingested substances was gathered from the patient, accompanying persons, and/or a body search. According to the protocol, blood samples for toxicological analysis were collected on the occasion of the vein cannulation. In case of micturition in the medical station, urine samples were also preserved. For patients transferred to a hospital, follow-up data were obtained retrospectively from the hospital charts. In these patients, urine samples were also collected. Patients for whom the drug assay proved to be negative were ultimately excluded from the toxicology study.

The study with an opting-out design was approved by the ethical committees of the four participating hospitals (University Hospital Ghent, General Hospital Jan Palfijn Ghent, General Hospital Saint Lucas Ghent, and General Hospital Maria Middelaers Ghent;

Belgium). The registration numbers are B670201318873 (for ILT 2013) and B670201422530 (for ILT 2014). The option-out design implied that blood and urine samples were obtained without consent. All included patients were given an information letter (eg, put in a plastic bag together with a cell phone and a wallet for a comatose patient transferred to a hospital). In this letter, the included attendants were invited to contact the principal investigator in order to obtain more information on the study and/or to express their will to be excluded from the study.

Drug Assay

For the toxicology study, all blood and urine samples were subjected to a standard systematic toxicological screening. Ethanol concentration was determined using headspace gas chromatographic-flame ionization detection. For urine and blood, the following were applied: gas chromatography-mass spectrometry (GC-MS) method, with commercially available libraries and high-performance liquid chromatographic (HPLC) method, combined with a diode-array detector (Agilent Technologies; Santa Clara, California USA) with an in-house developed library. Advanced toxicological analysis, such as LC-MS/MS, GC-MS, or GC-MS/MS, was performed for quantification of Δ^9 -tetrahydrocannabinol (THC) and its metabolites, cocaine, opioids, GHB, amphetamines, as well as benzodiazepines.^{16–19} For NPS detection and confirmation, commercially available MS libraries and LC-high-resolution tandem MS with an in-house developed library were used. The in-house target list comprised NPS from the following groups: cannabinoids, cathinones, phenylethylamines, piperazines, and tryptamines.²⁰

Additional Toxicological Analyses for the NPS Sub-Study

The initial toxicological screening for ethanol, THC, GHB, cocaine, and amphetamines was performed by trained toxicologists who were blinded regarding clinical presentation and the drug(s) ingested. The results of the toxicology study were independently cross-referenced with all available clinical data by two emergency physicians with special interest in party drugs. Whenever these two experts agreed on a discrepancy between the clinical and toxicological data, further toxicological analysis was requested. At this stage of the additional NPS sub-study, toxicologists were informed about the presenting symptoms. Only when advanced analysis yielded negative results, blinding was removed and information pointing to a particular drug (eg, conviction of mescaline ingestion) was revealed.

Results

The EDM event was attended by 30,000 and 26,000 people in 2013 and 2014, respectively.

A diagram of the studied populations is given in Figure 1.

The number of patients treated in the on-site medical station was 265 (88.3 per 10,000) in 2013 and 222 (85.4 per 10,000) in 2014. Among these patients, 38 were transferred to a hospital in 2013 (12.7 per 10,000) and 31 in 2014 (11.9 per 10,000).

Details regarding medical problems not related to alcohol or illicit drugs are presented in Table 1. Of particular interest were multiple robbery attempts with tear gas in 2014 (leading to 23 victims, including four transferred to a hospital).

The number of patients with drug-related problems was 89 in 2013 (29.6/10,000) and 71 in 2014 (27.3/10,000). The presenting symptoms are shown in Table 2. Hypoglycemia was excluded in all these patients. Only one agitated patient was hyperthermic, and one bradypnoeic patient was intubated endotracheally (Table 3).




Figure 1. Diagram of Study Populations.

Abbreviations: MDMA, 3,4-methylenedioxymethamphetamine; NPS, new psychoactive substances; THC, tetrahydrocannabinol.

* The toxicological screening in a patient remaining comatose for more than one hour was negative; this case is described in more detail in the sub-study on new psychoactive substances (NPS).

All patients admitted to a hospital were discharged within 18 hours.

According to the study protocol, blood samples were collected in 113 apparently intoxicated patients (67 in 2013 and 46 in 2014). None of these 113 patients asked to be excluded from the study. After review of the clinical data and based on negative toxicology, seven cases initially included in the toxicology study (six in 2013 and one in 2014) were excluded from the group with drug-related problems (and subsequently added to the cases not related to ethanol or illicit drugs). Fifty of the 106 cases included in the toxicology study (29/61 in 2013 and 21/45 in 2014) were transferred to a hospital.

For the 56 patients discharged from the on-site medical station after treatment, analytical toxicology revealed only ethanol in 31 patients (mean 2.0 g/L; range from 0.9 to 2.8 g/L). Three patients had consumed only MDMA (range: 464–609 ng/mL), and a further 13 patients had consumed both cannabis and ethanol (with ethanol concentrations between 0.3 and 2.4 g/L, and THC concentrations between 0.5 and 7.0 ng/mL). Among the 50 patients transferred to a hospital, only ethanol was found in 16 patients (mean 2.6 g/L; range from 1.9 to 4.0 g/L), only MDMA in three patients (range: 238–356 ng/mL), and a combination of ethanol and THC in four patients (with ethanol

concentrations between 0.9 and 3.0 g/L and THC concentrations between 0.5 and 2.9 ng/mL).

For the remaining 36 cases (ie, 27 transferred to a hospital and nine discharged from the on-site medical station), clinical and toxicological data (except the findings on NPS) are shown in Table 3 and Table 4. Intriguing was the patient transferred to a hospital with a presumed NPS intoxication. Also of particular interest were three patients where an intoxication with clozapine (a neuroleptic drug) was found; these intoxications most likely resulted from clozapine tablets sold as ecstasy during the event.²¹

An alternative presentation of the above-mentioned data from the 106 cases in the toxicology study (but without the results of the additional NPS sub-study) revealed ethanol in 97 patients (91.5%), MDMA in 36 (34.0%), THC in 32 (30.2%), cocaine in eight (7.5%), amphetamine in three and clozapine in three (2.8%), and ketamine in one and GHB in one (0.9%).

In 20 cases (nine in 2013 and 11 in 2014), the two clinicians requested additional toxicological analysis. The reasons for the inclusion in this NPS sub-study (ie, a presumed discrepancy between clinical data and the first set of toxicological data) were: discrepancy between level of depressed consciousness and toxicology (n=8), discrepancy between level of agitation and toxicology (n=3), and information on the intake of a particular drug not detected (n=9; MDMA in three cases, lysergic acid diethylamide in two cases, and four individuals assumed having ingested respectively mescaline, ketamine, a spiced drink, and sugar cubes impregnated with a drug causing convulsions). This stepwise toxicological approach revealed the presence of hallucinogenic phenethylamine derivatives 25B-NBOMe and 25C-NBOMe, in combination with ethanol (0.9 g/L) and THC (0.8 ng/mL), in an agitated patient. Particularly intriguing in this NPS sub-study was one patient who remained comatose for more than one hour with negative toxicology. As no cause for the depressed level of consciousness was detected during a 6-hour hospital stay, this case remained in the group of intoxicated patients (under the assumption that an NPS was ingested that was not present in the toxicological spectral libraries used for NPS identification).

The toxicological analysis of the urine samples (available in only 27 of the 106 included cases) provided no additional information.

Discussion

The findings in this study on the total number of treated patients, the number of patients transferred to a hospital after first assessment and treatment in the on-site medical station, and the numbers of patients with potentially life-threatening conditions (such as coma or convulsions) confirm the need of on-site, well-organized medical coverage during EDM events, mainly for incidents related to ethanol and/or illicit drug consumption.^{5–8} Indirectly, reports on dead party goers from other EDM events strongly suggest that Advanced Life Support providers in the field may save lives. Without any doubt, the deployment of medical teams at EDM events avoids many transfers to a hospital.^{5–8,22–25}

Main Findings in the Intoxicated Patients from this Study

The toxicology data in the present study revealed that the most prevalent substance used was ethanol: in up to 91.5% (97/106) ethanol was found, with ethanol being the only substance detected in 47.4% (46/97). Another figure underscoring the dominant role of ethanol was the 90.0% (45/50) prevalence of ethanol use in

	2013	2014
Trauma	86 (5)	85 (7)
Malaise, Vertigo	12	6
Headache	19	17
Abdominal Pain, Vomiting	24 (2)	20
Syncope	6	—
Convulsions	2 (1)	—
Psychogenic Hyperventilation	2	—
Chest Pain	1	1
Others	21	18 (1)
Unknown	3	4
Total	176 (8)	151 (8)

Calle © 2017 Prehospital and Disaster Medicine

Table 1. Presenting Symptoms Not Related to Ethanol or Illicit Drugs

Note: The number of patients transferred to a hospital is shown between brackets.

	2013	2014
Coma	7 (5)	3 (3)
Agitation/Anxiety	19 (13)	17 (12)
Convulsions	6 (5)	1 (1)
Syncope	9 (1)	10 (1)
Vomiting/Abdominal Pain	13	10
Chest Pain/Palpitations	4 (1)	1
Inebriety	29 (5)	23 (6)
Headache	2	5
Hallucinations	—	1
Total	89 (30)	71 (23)

Calle © 2017 Prehospital and Disaster Medicine

Table 2. Presenting Symptoms Related to Ethanol or Illicit Drugs

Note: The number of patients transferred to a hospital is shown between brackets.

patients transferred to a hospital, with ethanol being the only substance in 35.6% (16/45).

Second, among the “classic” illicit party drugs, only MDMA (34.0%) and cannabis (30.2%) were frequently detected. Worrisome is the observed poly-drug use in MDMA-positive cases. In only six cases, MDMA was the sole substance found (with concentrations between 238 and 609 ng/mL). Among the other 30 MDMA users, ethanol was most prevalent (found in 29 patients), followed by THC (11 patients), cocaine (six patients), and amphetamine (two patients). Most perturbing were the

six cases with MDMA concentrations above 800 ng/mL in combination with ethanol levels of at least 1.7 g/L (plus cocaine use in three).

Third, with regard to the use of GHB, ketamine, and all categories of NPS, the number of positive cases was low and the clinical presentations were rather mild.

A fourth point of interest was the discrepancy between toxicological data and the information provided concerning the ingested substance(s). There were seven cases where the presumed consumed drug was not found. Also, the three patients intoxicated with clozapine (assumed to be sold as ecstasy) were very remarkable. As this study was not designed to investigate this issue, these 10 cases were certainly an under-estimation. The dangers associated with this phenomenon were shown clearly by the clozapine case in need of intubation.^{10,11,21}

What are the Implications of the Above-Mentioned Toxicological Results?

In view of the time needed to perform all analyses, it is obvious that the patients and the treating physicians do not benefit from this laborious and costly research. Moreover, the therapy for all party drugs, including all known NPS, is symptom-driven (and not substance-specific or dose-dependent). Consequently, even point-of-care testing (if ever available) would rarely alter clinical decision making nor therapy.^{3,4} Therefore, the surplus value of this type of toxicological research involves mainly epidemiology and case histories (eg, the high-risk behavior of many MDMA users and the clozapine trickery), with the remark that extrapolating data from one event to another is troublesome. Nevertheless, up-to-date information on locally available party drugs (including dosage, color and logo on pills, contaminants, forgeries, and unusual clinical presentation) is important for potential users, medical caregivers, police forces, and political decision makers. For that purpose, scrutinized data from research projects performed during a particular event are useful, but only when combined with repetitive and wide-ranging surveys on drug use, a continuous program for in-depth chemical analysis on seized materials, and a nation-wide network of Emergency Medical Services, hospitals, and coroners collecting clinical and toxicological data.^{9–12,26}

The above-mentioned line of thought leads inevitably to the importance of all kinds of preventive measures: information and warnings to the attendants, close cooperation between the organizing committee and the law enforcement authorities to limit the on-site availability of illicit drugs, early detection and appropriate protective measures towards inebriated or intoxicated attendants, the on-site presence of properly trained and equipped medical care providers, and legal actions to classify NPS as illicit drugs. Whether or not pill testing/drug checking projects accessible for lay persons are valuable is a matter of (political/ethical) debate.²⁷ To some extent, these preventive measures on a particular EDM may be tailored by the results of locally performed toxicological studies.

Limitations

Some limitations of this study should be stressed.

First, the cases described were subject to selection bias regarding at least five items. The decision to bring a patient to the on-site medical station depended on many non-medical factors such as the attitude of friends/bystanders and the vigilance of stewards. Furthermore, the classification as a drug-related event,

Toxicological Findings (Only Blood Samples)	Presenting Symptoms
Ethanol 0.9 g/L + MDMA 210 ng/mL	Agitation
Ethanol 2.1 g/L + MDMA 472 ng/mL	Agitation
Ethanol 0.3 g/L + MDMA 575 ng/mL	Agitation
Ethanol 2.3 g/L + MDMA 253 ng/mL	Convulsions
Ethanol 0.7 g/L + MDMA 492 ng/mL	Agitation
Ethanol 2.2 g/L + MDMA 417 ng/mL	Agitation
Ethanol 1.9 g/L + MDMA 619 ng/mL	Agitation
Ethanol 2.0 g/L + MDMA 927 ng/mL	Agitation
Ethanol 2.6 g/L + MDMA 480 ng/mL	Agitation
Ethanol 1.7 g/L + MDMA 833 ng/mL	Agitation
Ethanol 2.5 g/L + MDMA 650 ng/mL + THC 3.6 ng/mL	Agitation
Ethanol 2.3 g/L + MDMA 480 ng/mL + THC 2.3 ng/mL	Convulsions
Ethanol 0.8 g/L + MDMA 160 ng/mL + THC 2.0 ng/mL	Agitation
Ethanol 1.9 g/L + MDMA 78 ng/mL + THC 1.9 ng/mL	Syncope
Ethanol 1.7 g/L + MDMA 166 ng/mL + THC 8.7 ng/mL	Chest Pain
Ethanol 1.1 g/L + MDMA 690 ng/mL + THC 0.7 ng/mL	Agitation
Ethanol 2.3 g/L + MDMA 1,510 ng/mL + THC 0.6 ng/mL	Agitation
Ethanol 2.8 g/L + MDMA 876 ng/mL + BE 614 ng/mL	Agitation
Ethanol 2.0 g/L + MDMA 956 ng/mL + BE 180 ng/mL	Agitation
Ethanol 2.2 g/L + MDMA 1,178 ng/mL + BE 124 ng/mL	Agitation + Hyperthermia
Ethanol 0.9 g/L + amphetamine 155 ng/mL + GHB 257 µg/mL	Agitation
Ethanol 1.9 g/L + MDMA 434 ng/mL + amphetamine 64 ng/mL + THC 0.6 ng/mL	Agitation
Ethanol 1.5 g/L + MDMA 646 ng/mL + BE 444 ng/mL + THC 9.2 ng/mL	Agitation
Ethanol 1.1 g/L + clozapine 243 ng/mL ^a	Agitation
Ethanol 0.7 g/L + clozapine 95 ng/mL + MDMA 635 ng/mL	Agitation
BE 182 ng/mL + MDMA 167 ng/mL + amphetamine 10 ng/mL + THC 2.7 ng/mL	Convulsions

Calle © 2017 Prehospital and Disaster Medicine

Table 3. Clinical and Toxicological Findings in 26 Cases Transferred to a Hospital because of Multi-Drug Use (with the exception of the combination of ethanol and cannabis)

Abbreviations: MDMA, 3,4-methylenedioxymethamphetamine; THC, tetrahydrocannabinol; GHB, gamma-hydroxybutyric acid; BE, benzoylecgonine (ie, the main metabolite of cocaine).

^aThis case was intubated three hours after transfer to the hospital because of recurrent episodes of bradypnea.

Toxicological Findings (Only Blood Samples)	Presenting Symptoms	Length-of-Stay in Medical Station
Ethanol 2.7 g/L + MDMA 478 ng/mL	Coma	55 min
Ethanol 1.4 g/L + MDMA 210 ng/mL	Vomiting	24 min
Ethanol 2.2 g/L + MDMA 478 ng/mL	Agitation	40 min
Ethanol 0.7 g/L + MDMA 399 ng/mL	Agitation	155 min
Ethanol 1.2 g/L + MDMA 282 ng/mL + THC 4.9 ng/mL	Syncope	19 min
Ethanol 2.2 g/L + MDMA 439 ng/mL + BE 160 ng/mL	Hallucinations	115 min
Ethanol 1.3 g/L + BE 135 ng/mL + THC 14 ng/mL	Chest pain	55 min
Ethanol 0.7 g/L + clozapine 73 ng/mL + THC 1 ng/mL	Syncope	16 min
BE 270 ng/mL + ketamine 20 ng/mL + THC 2.4 ng/mL	Vomiting	64 min

Calle © 2017 Prehospital and Disaster Medicine

Table 4. Clinical and Toxicological Findings in Nine Patients Who could be Discharged from the On-Site Medical Station (with the exception of the combination of ethanol and cannabis) (Abbreviations: MDMA, 3,4-methylenedioxymethamphetamine; THC, tetrahydrocannabinol; BE, benzoylecgonine (ie, the main metabolite of cocaine)).

the instruction to insert an intravenous line (ie, the starting point for the inclusion in the intoxication study), and the decision to hospital transfer may vary from one emergency physician to another, especially because most decisions were taken under pressure within a short period of time and/or without sufficient information. In addition, the request for an additional NPS toxicological analysis was impossible to standardize and therefore also bias-prone. Some examples of the (almost inevitable) risk of selection bias in this study are the seven cases initially included in the toxicology study (eg, because of syncope or convulsions) but subsequently excluded as toxicology was negative, the three cases that were included but could be discharged from the on-site medical station within 30 minutes (Table 4), and the intriguing case from the NPS sub-study remaining comatose for more than one hour with negative toxicology.

Second, important pieces of information were lacking or unreliable for many patients, despite the on-site presence of medical students having no other task than collecting and registering data.

Third, toxicologists can never be 100% sure about the absence of illicit drugs since many substances (especially NPS) are active at very low concentrations. Moreover, the number of NPS is seemingly unending.^{9–11} This issue is perfectly illustrated by the 25B-NBOMe/25C-NBOMe case. These NPS were only detected during the third toxicological search, and necessitated the use of innovative equipment and techniques.^{13,20}

It is important to mention that the above-mentioned methodological limitations are practically inescapable and that very few studies collected toxicological data as rigorously as in the present study. Indeed, other studies only analyzed data collected

retrospectively (using chart review) or classified drug use with only a limited number of toxicological tests, or even without any toxicological analysis at all.^{5,7,8,22–25,28} For all these reasons, any comparison between studies or extrapolation from one music event to another have to be done with great caution.

Conclusion

The results of the present study confirm the need for on-site, well-organized medical coverage during EDM events, mainly for

incidents related to ethanol and/or illicit drugs. The most prevalent substance was ethanol. Most worrying was the high-risk, poly-drug use, especially among MDMA users where very high MDMA concentrations were observed. Regarding GHB, ketamine, and all categories of NPS, the numbers of cases were low and the clinical presentations rather mild. Extrapolating these findings to other events should be done with great caution as each event has its own particularities and considerable selection bias influences data gathering in this kind of study.

References

1. Van Havere T, Vanderplassen W, Lammertyn J, Broekaert E, Bellis M. Drug use and nightlife: more than just dance music. *Subst Abuse Treat Prev Policy*. 2011; 6:18–29.
2. Palamar JJ, Thomas MG, Ompad DC. Illicit drug use among rave attendees in a nationally representative sample of US high school seniors. *Drug Alcohol Depend*. 2015;152:24–31.
3. Novel Psychoactive Treatment UK Network NEPTUNE. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances. 2015. <http://neptune-clinical-guidance.co.uk/>. Accessed February 24, 2017.
4. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. *Emerg Med Clin North Am*. 2014;32(1):1–28.
5. Krul J, Blankers M, Girbes AR. Substance-related health problems during rave parties in the Netherlands. *PLoS ONE*. 2011;6(12):e29620.
6. Van Sassenbroeck DK, Calle PA, Rousseau FM, et al. Medical problems related to recreational drug use at nocturnal dance parties. *Eur J Emerg Med*. 2003;10(4): 302–308.
7. Ridpath A, Driver CR, Nolan ML, et al. Illnesses and deaths among persons attending an electronic dance-music festival – New York City, 2013. *MMWR Morb Mortal Wkly Rep*. 2014;63(50):1195–1198.
8. Lund A, Turris SA. Mass-gathering medicine: risks and patient presentations at a 2-day electronic dance music event. *Prehosp Disaster Med*. 2015;30(3):271–278.
9. European Drug Report – Trends and Developments 2016. European Monitoring Centre for Drugs and Drug Addiction publication. EMCDDA Europol, Lisbon; May 2016. <http://www.emcdda.europa.eu/publications/eu-drug-markets/2016/strategic-overview>. Accessed February 24, 2017.
10. Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the poisons information center. *Drug Alcohol Depend*. 2015;147:109–115.
11. Helander A, Bäckberg M, Hultén P, Al-Saffar Y, Beck O. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. *Forensic Sci Int*. 2014;243:23–29.
12. Blanckaert P, van Amsterdam J, Brunt T, et al. 4-methyl-amphetamine: a health threat for recreational amphetamine users. *J Psychopharmacol*. 2013;27(9):817–822.
13. Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin ML, Chen HH, Sanchez LA. Pathological findings in 2 cases of fatal 25I-NBOME toxicity. *Am J Forensic Med Pathol*. 2014;35(1):20–25.
14. World Health Organization (WHO). Global status report on alcohol and health 2014. http://www.who.int/substance_abuse/publications/global_alcohol_report/en/. Published 2014. Accessed February 24, 2017.
15. Gogaert S, Vande Veegaete A, Scholliers A, Vandekerckhove P. MedTRIS (Medical Triage and Registration Informatics System): a web-based client server system for the registration of patients being treated in first aid posts at public events and mass gatherings. *Prehosp Disaster Med*. 2016;31(5):557–562.
16. del Mar Ramirez Fernandez M, De Boeck G, Wood M, Lopez-Rivadulla M, Samyn N. Simultaneous analysis of THC and its metabolites in blood using liquid chromatography-tandem mass spectrometry. *J Chromatogr B*. 2008;875(2): 465–470.
17. del Mar Ramirez Fernandez M, Wille SMR, Kummer N, Di Fazio V, Ruysinckx E, Samyn N. Quantitative Analysis of 26 opioids, cocaine, and their metabolites in human blood by ultra-performance liquid chromatography-tandem mass spectrometry. *Ther Drug Monit*. 2013;35(4):510–521.
18. Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. *Forensic Sci Int*. 2003;133(1–2):9–16.
19. del Mar Ramirez Fernandez M, Samyn N. Ultra-performance liquid chromatography-tandem mass spectrometry method for the analysis of amphetamines in plasma. *J Anal Toxicol*. 2011;35(8):577–582.
20. Kinyua J, Negreira N, Ibáñez M, et al. A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples. *Anal Bioanal Chem*. 2015;407(29):8773–8785.
21. Calle S, Patteet L, Maudens K, et al. Did the Walking Dead appear at a dance event? Paper presented at: MEMC-GREAT 2015 Joint Congresses, September 5–9, 2015; Rome, Italy. https://issuu.com/aaeminfo/docs/poster_abstracts_-_tuesday_T209. Accessed February 24, 2017.
22. Ganguly S, Friedman MS. Raves and saves: massive music festivals call for advanced emergency care. <http://epmonthly.com/article/raves-and-saves-the-need-for-advanced-emergency-management-at-mass-gatherings/>. Accessed February 24, 2017.
23. Ferguson GM. Dayglow incident sheds light on growing EMS problems of dance parties. <http://www.jems.com/articles/2011/12/dayglow-incident-sheds-light-growing-ems.html>. Accessed February 24, 2017.
24. Wood DM, Beaumont PO, May D, Dargan PI. Recreational drug use presentations during a large outdoor festival event: reduction in hospital emergency department transfer where medical physicians are present. *J Substance Use*. 2010;15(6): 434–441.
25. Chapple J. 17 deaths and 100+ overdoses: a year in live EDM. <http://www.iq-mag.net/2016/05/17-deaths-100-overdoses-year-edm/#.WBBsXYVOKM8>. Accessed February 24, 2017.
26. Heyerdahl F, Hovda KE, Giraudon I, et al. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. *Clin Toxicol*. 2014;52(10):1005–1012.
27. Ritter A. Six reasons Australia should pilot 'pill testing' party drugs. <http://theconversation.com/six-reasons-australia-should-pilot-pill-testing-party-drugs-34073>. Accessed February 24, 2017.
28. Krul J, Girbes AR. γ -hydroxybutyrate: experience of 9 years of γ -hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. *Clin Toxicol*. 2011; 49(4):311–315.